Cannabis Law Report

DECEMBER 3, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Extended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up. change in MMSF).

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. This means that the medical and scientific communities can now celebrate broader access to research for the production of pharmaceutical products that are safer than smokable or vaporizable cannabis. The post New U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. Chief Medical Officer of Marinus. “We Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

MMJ Recs

FEBRUARY 18, 2024

This comprehensive article aims to explore the myriad health benefits of medical marijuana, delving into its therapeutic potential, impact on mental health, role in managing chronic conditions, and the holistic healing it offers, with a special focus on cannabinoids like CBD.

Chronic Pain 52

Chronic Pain Marijuana Epilepsy Research and Development 52

Cannabis Law Report

SEPTEMBER 28, 2021

In most situations, it is related to another chronic condition that cannot be cured quickly or at all. Acupuncture is one of the safest alternative forms of treatment for chronic pain. Ideally, it should be used in combination with other therapies, such as herbal medicine and massage, and can be a great addition to other treatments.

Treatment 52

Treatment Chronic Pain Therapy Tincture 52

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies.

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D.,

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

SpeedWeed

JUNE 14, 2021

State officials tasked with overseeing Ohio’s medical marijuana program approved last week the addition of three health conditions that qualify a patient to use cannabis medicinally. Spasticity is a medical condition characterized by prolonged muscle contraction and abnormal muscle tightness. List Of Conditions Reviewed Annually.

Conditions 40

Conditions Programs Therapy Patients 40

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. Of course, it’s wonderful to see the FDA approve this substance to help those suffering from this rare condition.

Access 98

Access Epilepsy Treatment Conditions 98

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

United Patients Group

APRIL 18, 2023

Because they often combine it with other drugs like cocaine or heroin or even legal ‘prescribed’ pharmaceuticals–and those are far more dangerous than cannabis itself! Another example, Age, weight, current health condition, sensitivities and even drug to drug interactions should be addressed. Myth: One size fits all.

Research and Development 110

Research and Development Indica Treatment Conditions 110

Cannabis Law Report

AUGUST 4, 2022

Following the keenly anticipated June approval of its cannabis-derived Epidiolex, GW Pharmaceuticals $GWPH has finally launched the rare epilepsy drug in the United States. GW has set a list price of $1,235 per 100 ml bottle for the oral seizure treatment, GW spokesperson Stephen Schultz told Endpoints News. Press Release.

Epilepsy 52

Epilepsy Therapy Patients Treatment 52

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. The first batch of authorized pharmaceutical retailers is expected to start selling between late August and early September. And Turnage has hinted that the regulation would be formalized soon.

Oil 98

Oil Patients Access THC 98

Veriheal

SEPTEMBER 27, 2021

Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? The condition can have a devastating impact on its host, causing excessive pain and neurological dysfunction. 1, MS Society UK posted on Twitter , “Getting the treatment you need shouldn’t be a game of chance.

Treatment 98

Treatment Patients Access Research and Development 98

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

TheAnswerPage

JUNE 29, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. Has CBDV been evaluated as an anti-seizure medication in clinical trials? That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

TheAnswerPage

MAY 20, 2022

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? Regulatory approval has been obtained in numerous countries outside the United States for the treatment of multiple sclerosis symptoms (nerve pain, spasticity, overactive bladder, and other symptoms).

Nerve Pain 52

Nerve Pain Epilepsy Pharmaceutical Cannabinoids 52

TheAnswerPage

JANUARY 9, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. Has CBDV been evaluated as an anti-seizure medication in clinical trials? That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JULY 24, 2019

But it is important that access to it is delivered in a way that fits in with other treatment options. Our clinics are based on the premise that patients are treated by our world-renowned specialists in the relevant condition.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

MMJ Recs

FEBRUARY 3, 2024

This guide aims to navigate the intricate web of cannabis legislation in Philadelphia, Pennsylvania, exploring key aspects such as medical marijuana laws, cannabis regulations, qualifying conditions, patient eligibility, and the overall impact on the local cannabis industry.

Legislation 52

Legislation Law Marijuana Dispensary 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. In 2020, the law changed to allow patients with any medical condition to receive a doctor’s recommendation to use and purchase medical marijuana products containing a maximum 10 milligrams of THC.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

TheAnswerPage

JULY 13, 2021

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. Has CBDV been evaluated as an anti-seizure medication in clinical trials? That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

TheAnswerPage

AUGUST 19, 2021

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? Regulatory approval has been obtained in numerous countries outside the United States for the treatment of multiple sclerosis symptoms (nerve pain, spasticity, overactive bladder, and other symptoms).

Nerve Pain 52

Nerve Pain Epilepsy Pharmaceutical Cannabinoids 52

PrestoDoctor

OCTOBER 13, 2023

Marinol, also known as Dronabinol, is a medication used to treat a variety of conditions, including nausea and vomiting caused by chemotherapy, loss of appetite and weight loss in people with HIV/AIDS, as well as chronic pain. However, unlike marijuana, Marinol is a FDA-approved pharmaceutical drug.

THC 98

THC Chronic Pain Treatment Conditions 98

CannaMD

JULY 14, 2020

With modern medicine advancing at an astounding rate, new medications and treatments are becoming available to treat nearly every ailment life throws at you. Polypharmacy is a growing problem where patients are prescribed multiple different medications simultaneously in order to treat a given medical condition. WHAT IS POLYPHARMACY?

Marijuana 105

Marijuana Conditions Patients Epilepsy 105

TheAnswerPage

JUNE 14, 2021

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? Regulatory approval has been obtained in numerous countries outside the United States for the treatment of multiple sclerosis symptoms (nerve pain, spasticity, overactive bladder, and other symptoms).”

Nerve Pain 52

Nerve Pain Epilepsy Pharmaceutical Cannabinoids 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Cannigma

JUNE 25, 2022

Poland established a medical cannabis program in 2017, which allows for a range of cannabis products to be prescribed for a range of medical conditions. Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products. Poland and cannabis.

Legalization 108

Legalization Supply Chain Chronic Pain Tincture 108

MGC Pharma

DECEMBER 12, 2017

A word from Elad Segev, Manager of Breeding and Cultivation at MGC Pharmaceuticals. This effect can be put to very good use to help patients suffering from cancer or HIV/AIDS eliminate any uncomfortable nausea that their treatments provoke. It’s also effective in treating patients with refractory epilepsy who experience daily seizures.

Epilepsy 100

Epilepsy Cannabinoids Pharmaceutical THC 100

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

Medical marijuana laws have changed dramatically across the country in recent years, and now cannabis pharmaceuticals appear to be the next big leap forward in cannabis law reform. Epidiolex has received FDA approval to treat Dravet Syndrome and Lennox-Gestaut Syndrome; two very rare forms of epilepsy that manifest in early childhood.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97